FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL							
OMB Number: 3235-028							
Estimated average burden							
hours per response:	0.5						

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* Thompson Jave					2. Issuer Name and Ticker or Trading Symbol Greenwich LifeSciences, Inc. [GLSI]										Relationship of Reporting Person(s) to Issuer (Check all applicable) Director					
(Last)	3. Date of Earliest Transaction (Month/Day/Year) 02/03/2023									X	Officer (g below)		Other (specify below)		specify					
C/O GREENWICH LIFESCIENCES, INC.															VP Clinical Reg Affairs					
3992 BLUEBONNET DR., BUILDING 14				4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Indiv	6. Individual or Joint/Group Filing (Check Applicable Line)							
,														X	X Form filed by One Reporting Person					
(Street)															Form file	d by More	than O	ne Reportin	g Person	
STAFFORD	TX	77	477																	
(City)	(State)	(Zij	o)																	
		Та	ble I - Nor	n-Deri	ivativ	e Se	curitie	s Acqı	uired, l	Disp	osed of,	or l	Benefi	cially Ow	/ned					
Date				nth/Day/Year) if		2A. Deemed Execution Date, if any (Month/Day/Year)					ties Acquired (A) or I Of (D) (Instr. 3, 4 ar			5. Amount of Securities Beneficially Owned Following Reported Transaction(s)		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership (Instr. 4)		
								Code	v	Amount		(A) or (D)	Price	(Instr. 3 and 4)				L		
Common Stock 02/0					/03/2023				P		250		Α	\$20.84	257,245			D		
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																				
1. Title of Derivative Security (Instr. 3)	ative Conversion Date Execution Date, if any			4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		te	7. Title and Amo Securities Unde Derivative Secu (Instr. 3 and 4)		derlying curity	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)		
					Code	v	(A)	(D)	Date Exercisa		Expiration Date	Title	•	Amount or Number of Shares		(Instr. 4)	J.11(3)			

Explanation of Responses:

/s/ Jaye Thompson

02/07/2023

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

 $^{^{\}star}$ If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

^{**} Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).